Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

BACKGROUND: Lebrikizumab is a monoclonal antibody that binds with high affinity to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. OBJECTIVES: To report integrated safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis from...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein Gold, Linda, Thaçi, Diamant, Thyssen, Jacob P., Gooderham, Melinda, Laquer, Vivian, Moore, Angela, Natalie, Chitra R., Zhao, Fangyi, Meskimen, Eric, Elmaraghy, Hany, Montmayeur, Sonia, Gallo, Gaia, Jimenez, Gemma, de Bruin-Weller, Marjolein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191071/
https://www.ncbi.nlm.nih.gov/pubmed/37195407
http://dx.doi.org/10.1007/s40257-023-00792-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191071/
https://www.ncbi.nlm.nih.gov/pubmed/37195407
http://dx.doi.org/10.1007/s40257-023-00792-6

Ejemplares similares